Navigation Links
Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
Date:5/18/2011

r persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures.

Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar. Caution is recommended when administering Nexavar with compounds that are metabolized/eliminated predominantly by the UGT1A9 pathway, UGT1A1 pathway (eg, irinotecan), doxorubicin, docetaxel, fluorouracil, and substrates of CYP2B6 and CYP2C8, and CYP3A4 inducers.

Concomitant use of carboplatin and paclitaxel with sorafenib resulted in an increase in paclitaxel exposure and an increase in Nexavar exposure. Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time, INR, or clinical bleeding episodes. Nexavar exposure decreases when co-administered with oral neomycin. Effects of other antibiotics on Nexavar pharmacokinetics have not been studied.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs 25%), fatigue (46% vs 45%), abdominal pain (31% vs 26%), weight loss (30% vs 10%), anorexia (29% vs 18%), nausea (24% vs 20%), and hand-foot skin reaction (21% vs 3%). Grade 3/4 adverse reactions were 45% vs 32%.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.

During postapproval use of Nexavar, the following adverse drug reactions have been identified: angioedema and drug-induced hepatitis, including reports of hepatic failure and death.

For info
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
2. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
3. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
4. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
5. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
6. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
9. Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
10. Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
11. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  MiMedx Group, Inc.  (NASDAQ: ... marketer of patent-protected regenerative biomaterials and bioimplants processed ... filed its initial Investigational New Drug ("IND") application ... The IND submission, which was filed ... submission for certain indications of its micronized allografts ...
(Date:7/23/2014)...  Dompe, a leader in R&D for new therapeutic solutions ... Human Nerve Growth Factor) has been designated as an orphan ... The candidate drug, developed by the research of ... treatment of neurotrophic keratitis, a degenerative corneal disease that affects ... currently without a cure. This is the second orphan drug ...
(Date:7/23/2014)... DUBLIN , July 23, 2014 ... addition of the "Prepackaged Medical Kits and ... to their offering. ... worldwide markets for Prepackaged Medical Kits and Trays ... ENT Custom Trays, Ophthalmic Custom Trays, Custom Basin ...
Breaking Medicine Technology:MiMedx Files Its Initial Investigational New Drug Application 2MiMedx Files Its Initial Investigational New Drug Application 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2
... The SAP® Customer Relationship Management (SAP CRM) application, configured ... enabled by Freudenberg IT (FIT), is powering the complex sales and ... in stem cell cryopreservation services. , ... SAP CRM 7.0, provided by RunE2E, enables ...
... , VANCOUVER , May 17 Xenon Pharmaceuticals Inc. ... Mansour as Executive Vice President, Research and Development. , ... "We are delighted to welcome Tarek ... CEO. "Tarek is a world-class R&D executive whose experience in discovering products, ...
Cached Medicine Technology:RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud 2RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud 3RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud 4Xenon Announces Appointment of EVP, Research & Development 2
(Date:7/23/2014)... CA (PRWEB) July 23, 2014 “Unlike ... will focus on developing your own unique gifts, talents ... techniques and clichéd sales verbiage, “says Ja Marr Brown. ... Your Sales Story?" which chronicles Brown’s transformation from nearly ... Person of The Year, winning every sales contest offered ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... overwhelming ratified today a robust trial for a ... implications of risk adjusting relevant quality measures for ... to NQF policy.     , Sociodemographic factors can be ... e.g., race, ethnicity, and primary language. Growing ...
(Date:7/23/2014)... Worth, FL (PRWEB) July 23, 2014 ... take place Aug. 10-16, Millennium Treatment Group is providing ... abuse has existed in society ever since man first ... wine. Substance abuse treatment has existed since shortly thereafter. ... recognizing a problem and then developing a way to ...
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 Inventor ... America: From football games to the gas pump – ... guests on Wednesday, July 30 at Noon. , With ... Legislator has more patents than anyone in the General ... football’s superimposed yellow line yard marker as seen on ...
Breaking Medicine News(10 mins):Health News:Using Your Story and Not Technique to Achieve Sales Success 2Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Celebrating Innovation and Invention 2
... woman with dementia, little money and an equally aged caregiver sister who ... woman with Alzheimer,s who cannot be left safely on her own, forcing ... A 78-year-old Los Angeles man with Alzheimer,s ... him if day care services are cut. These ...
... the body,s chemical response to injury , THURSDAY, Oct. 1 ... were injured were more likely to survive than sober trauma ... similar finding. , The latest study of 7,985 trauma patients ... 1 percent of intoxicated patients. All of the patients were ...
... ... media supplements, Zap-CHO and Optiferrin, have been developed to maximize cell culture media performance ... bioprocessing industry, October 12-16 at Raleigh Convention Center in Raleigh, North Carolina. , ... Fort Collins, CO (PRWEB) ...
... , Effort Illustrates Broad Public Support for Addressing ... Oct. 1 Citizens of Delaware ... prevention and wellness with the launch today of "Say ,Yes, ... online video campaign of the Partnership to Fight Chronic Disease ...
... Oct. 1 Cynthia Perkins, M.Ed., publishes new book, ... , to provide alcoholics with the little known facts ... Stay Sober: The Truth About Alcoholism provides an ... and its successful treatment! Despite past decades of unrelenting ...
... 1 Reportlinker.com announces that a new market research ... World Pharmaceutical Packaging , http://www.reportlinker.com/p0127773/World-Pharmaceutical-Packaging.html ... 2013 Global demand for pharmaceutical packaging will rise ... 2013. The developed countries of Western Europe, the US ...
Cached Medicine News:Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 2Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 3Health News:InVitria's Better Ingredients for Better Media to be Showcased at BPI '09 2Health News:Delaware Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 2Health News:Delaware Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 3Health News:New Book Provides Alcoholics with Hope for Stable, Long-Term, Craving-Free Sobriety 2Health News:Reportlinker Adds World Pharmaceutical Packaging Report 2Health News:Reportlinker Adds World Pharmaceutical Packaging Report 3Health News:Reportlinker Adds World Pharmaceutical Packaging Report 4Health News:Reportlinker Adds World Pharmaceutical Packaging Report 5Health News:Reportlinker Adds World Pharmaceutical Packaging Report 6Health News:Reportlinker Adds World Pharmaceutical Packaging Report 7Health News:Reportlinker Adds World Pharmaceutical Packaging Report 8Health News:Reportlinker Adds World Pharmaceutical Packaging Report 9Health News:Reportlinker Adds World Pharmaceutical Packaging Report 10
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
Medicine Products: